BBIO BridgeBio Pharma Inc.

33.02
+0.82  (+3%)
Previous Close 32.2
Open 32.35
Price To Book 8.88
Market Cap 4,080,445,410
Shares 123,574,967
Volume 203,694
Short Ratio
Av. Daily Volume 261,123
Stock charts supplied by TradingView

NewsSee all news

  1. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the

  2. BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

    BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug

  3. PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

    - Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment

  4. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its

  5. BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

    AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2021.
AG10 / BBP-265 - ATTRibute-CM
ATTR-CM
Phase 3 trial planned for 1Q 2020.
AG10 / BBP-265
ATTR-PN
Phase 2 pivotal trial data due 2020.
BBP-831
Cholangiocarcinoma
Phase 3 trial to commence 2020.
BBP-831
Achondroplasia
Phase 3 completion of enrolment announced December 2, 2019.
BBP-009/Patidegib
Gorlin syndrome
Phase 2b trial to commence in 2019.
BBP-009
High-Frequency Basal Cell Carcinoma
Rolling NDA initiation announced December 3, 2019.
Fosdenopterin (BBP-870/ORGN001)
Molybdenum cofactor deficiency type A
Phase 1/2 data due 2020.
BBP-589
Epidermolysis bullosa

Latest News

  1. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the

  2. BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

    BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug

  3. PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

    - Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment

  4. BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its

  5. BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

    AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)

  6. BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

    Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2iEnded quarter with $446.1 million in

  7. Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

    SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third

  8. BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

  9. Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

    PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,